Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity - PubMed (original) (raw)
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
G Gross et al. Proc Natl Acad Sci U S A. 1989 Dec.
Abstract
To design and direct at will the specificity of T cells in a non-major histocompatibility complex (MHC)-restricted manner, we have generated and expressed chimeric T-cell receptor (TcR) genes composed of the TcR constant (C) domains fused to the antibody's variable (V) domains. Genomic expression vectors have been constructed containing the rearranged gene segments coding for the V region domains of the heavy (VH) and light (VL) chains of an anti-2,4,6-trinitrophenyl (TNP) antibody (SP6) spliced to either one of the C-region gene segments of the alpha or beta TcR chains. Following transfection into a cytotoxic T-cell hybridoma, expression of a functional TcR was detected. The chimeric TcR exhibited the idiotope of the Sp6 anti-TNP antibody and endowed the T cells with a non-MHC-restricted response to the hapten TNP. The transfectants specifically killed and produced interleukin 2 in response to TNP-bearing target cells across strain and species barriers. Moreover, such transfectants responded to immobilized TNP-protein conjugates, bypassing the need for cellular processing and presentation. In the particular system employed, both the TNP-binding site and the Sp6 idiotope reside almost exclusively in the VH chain region. Hence, introduction into T cells of TcR genes containing only the VHSp6 fused to either the C alpha or C beta was sufficient for the expression of a functional surface receptor. Apparently, the VHC alpha or VHC beta chimeric chains can pair with the endogenous beta or alpha chains of the recipient T cell to form a functional alpha beta heterodimeric receptor. Thus, this chimeric receptor provides the T cell with an antibody-like specificity and is able to effectively transmit the signal for T-cell activation and execution of its effector function.
Similar articles
- Functional assembly of chimeric T-cell receptor chains.
Gorochov G, Lustgarten J, Waks T, Gross G, Eshhar Z. Gorochov G, et al. Int J Cancer Suppl. 1992;7:53-7. Int J Cancer Suppl. 1992. PMID: 1428405 - Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation.
Goverman J, Gomez SM, Segesman KD, Hunkapiller T, Laug WE, Hood L. Goverman J, et al. Cell. 1990 Mar 23;60(6):929-39. doi: 10.1016/0092-8674(90)90341-b. Cell. 1990. PMID: 2138514 - Production and characterization of genetically engineered antibody molecules.
Morrison SL, Canfield S, Porter S, Tan LK, Tao MH, Wims LA. Morrison SL, et al. Clin Chem. 1988 Sep;34(9):1668-75. Clin Chem. 1988. PMID: 3138036 Review. - Endowing T cells with antibody specificity using chimeric T cell receptors.
Gross G, Eshhar Z. Gross G, et al. FASEB J. 1992 Dec;6(15):3370-8. doi: 10.1096/fasebj.6.15.1464371. FASEB J. 1992. PMID: 1464371 Review.
Cited by
- Developing CAR T-Cell Therapies for Pediatric Solid Tumors.
Canciani G, Fabozzi F, Pinacchio C, Ceccarelli M, Del Bufalo F. Canciani G, et al. Paediatr Drugs. 2024 Oct 9. doi: 10.1007/s40272-024-00653-7. Online ahead of print. Paediatr Drugs. 2024. PMID: 39382819 Review. - Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies.
Zhou S, Yang Y, Jing Y, Zhu X. Zhou S, et al. Front Immunol. 2024 Sep 20;15:1435635. doi: 10.3389/fimmu.2024.1435635. eCollection 2024. Front Immunol. 2024. PMID: 39372412 Free PMC article. Review. - Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.
Ren T, Huang Y. Ren T, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep 24. doi: 10.1007/s00210-024-03443-7. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 39316087 Review. - Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment.
Chang Y, Chang M, Bao X, Dong C. Chang Y, et al. Bioact Mater. 2024 Sep 10;42:379-403. doi: 10.1016/j.bioactmat.2024.08.046. eCollection 2024 Dec. Bioact Mater. 2024. PMID: 39308543 Free PMC article. Review. - ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights.
Ali A, DiPersio JF. Ali A, et al. Front Immunol. 2024 Sep 5;15:1432799. doi: 10.3389/fimmu.2024.1432799. eCollection 2024. Front Immunol. 2024. PMID: 39301026 Free PMC article. Review.
References
- Nature. 1983 Mar 24-30;302(5906):340-2 - PubMed
- Proc Natl Acad Sci U S A. 1982 Dec;79(23):7425-9 - PubMed
- J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
- Nature. 1985 Mar 28-Apr 3;314(6009):330-4 - PubMed
- Nature. 1985 Oct 3-9;317(6036):430-4 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials